Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosa.

Samuel G. Jacobson(Penn Presbyterian Medical Center), Edwin M. Stone(Instituto da Visão), Eric A. Pierce(Broad Institute), Artur V. Cideciyan(University of Pennsylvania), Louisa M. Affatigato, Jean Bennett(Penn Presbyterian Medical Center), Alessandro Iannaccone(University of North Carolina at Chapel Hill), Michael Danciger, Albert M. Maguire(Children's Hospital of Philadelphia), Debora B. Farber(Doheny Eye Institute), Gerald A. Fishman(University of Illinois Urbana-Champaign), Richard G. Weleber(Oregon Health & Science University)
PubMed
June 1, 2000
Cited by 132

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864